NEW YORK, May 14, 2021 /PRNewswire/ -- The global
anaplastic lymphoma kinase (ALK) inhibitors market by type
(second-generation ALK inhibitors, first-generation ALK inhibitors,
and third-generation ALK inhibitors) and geography (North America, Europe, Asia,
and ROW) has been added to Technavio's offering. The global
anaplastic lymphoma kinase (ALK) inhibitors market is expected to
grow by USD 3.43 billion, at a CAGR
of almost 22% during 2021-2025.
Request a Free Sample Report to Know
More
The market witnessed a slight decline in the sales of ALK
inhibitors in 2020 as several scheduled treatments were either
delayed or postponed. Besides, the high incidence of COVID-19 in
the second wave has limited the movement of people, which has
disrupted the supply chain and logistic operations. These factors
are expected to hinder the growth of the ALK inhibitors market to
some extent during the forecast period.
The market is expected to be driven by factors such as the high
target affinity and specificity of ALK inhibitors, the high
prevalence of lung cancer, and the presence of patient assistance
programs.
The report also offers information on the upcoming trends and
challenges that will influence market growth.
Download Our Free Sample Report
Anaplastic Lymphoma Kinase (ALK) Inhibitors Market:
Opportunities
The rising consumption of tobacco and the passive inhalation of
poisonous gases have increased the prevalence of lung disorders
globally. In addition, the growing prevalence of cancer, including
NSCLC, and the increasing need for promising therapeutics are
driving the demand for ALK inhibitors. Besides, the increasing
awareness about ALK inhibitors among patients and the wide
availability of different ALK inhibitors are expected to provide
several growth opportunities in the global anaplastic lymphoma
kinase inhibitors market during the forecast period.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Market:
Segmentation by Type
Based on the segmentation by type, the market generated maximum
revenue in the second-generation ALK inhibitors segment in 2020.
The segment is driven by the increasing regulatory approvals of
second-generation ALK inhibitors. Also, the rising prevalence of
cancer is expected to fuel the growth of the segment during the
forecast period.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Market:
Segmentation by Geography
North America held the largest
market share in 2020 and the market growth in the region is
expected to be faster compared to the growth of the market in other
regions. The growth of the market in North America can be attributed to the high
sales of approved ALK inhibitors and the increasing prevalence of
lung cancer. In addition, an increase in R&D spending by
vendors is expected to contribute to the growth of the ALK
inhibitors market in North America
during the forecast period.
One of the fortune 500 companies had used the detailed research
report on the anaplastic lymphoma kinase (ALK) inhibitors market
and had decided to increase their market share in the North
American region which offers the highest market opportunities
during the forecast period.
Explore more about market
opportunities: Enquire about the report before
purchasing
Anaplastic Lymphoma Kinase (ALK) Inhibitors Market: Major
Vendors
Betta Pharmaceuticals Co. Ltd.
The company is involved in developing X-396. This molecule is
under clinical phase II evaluated as an ALK inhibitor for lung
cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
The company sponsored the study on TQ-B3139, which is a
competitive multi-target protein kinase inhibitor of
Met/ALK/ROS.
F. Hoffmann-La Roche Ltd.
The company caters ALECENSA, which is indicated for the
treatment of patients with ALK-positive metastatic NSCLC as
detected by an FDA-approved test.
Helsinn Healthcare SA
The company through a co-promotion agreement with Novartis for
Zykadia provides detailing services for Zykadia in the US. Zykadia
is an approved treatment for patients with metastatic NSCLC whose
tumors are ALK-positive.
Takeda Pharmaceutical Co. Ltd.
The company provides ALUNBRIG (brigatinib), which is a
prescription medicine used to treat people with NSCLC. It blocks
certain proteins made by the ALK gene.
Along with the market data, Technavio offers customizations as
per the specific needs of companies. The following customization
options are available for the anaplastic lymphoma kinase (ALK)
inhibitors market report:
Regional Analysis
- Further breakdown of the market segmentation at requested
regions.
Market Player Information
- Detailed analysis and profiling of additional market players,
vendor segmentation, and vendor offerings.
- Know the strategies adopted by vendors during the COVID-19
Recovery Phase.
Speak to our Analyst for a Customized
Report
Related Reports on Anaplastic Lymphoma Kinase (ALK)
Inhibitors Market:
Global Selective Serotonin Reuptake Inhibitors (SSRIs)
Market – Global selective serotonin reuptake inhibitors
(SSRIs) market is segmented by application (depression, anxiety and
panic disorder, and other mental conditions) and geography
(North America, Europe, Asia,
and ROW).
Download Exclusive Free Sample Report
Global PARP (Poly ADP-ribose Polymerase) Inhibitors
Market – Global PARP (poly adp-ribose polymerase)
inhibitors market is segmented by end-user (ovarian cancer, breast
cancer, and others) and geography (North
America, Europe, APAC,
South America, and MEA).
Download Exclusive Free Sample Report
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Second-generation ALK inhibitors - Market size and forecast
2020-2025
- First-generation ALK inhibitors - Market size and forecast
2020-2025
- Third-generation ALK inhibitors - Market size and forecast
2020-2025
- Market opportunity by Type
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size
and forecast 2020-2025
- Europe - Market size and
forecast 2020-2025
- Asia - Market size and
forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Betta Pharmaceuticals Co. Ltd.
- Bio-Techne Corp.
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Helsinn Healthcare SA
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Turning Point Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions. With over 500 specialized analysts,
Technavio's report library consists of more than 17,000 reports and
counting, covering 800 technologies, spanning across 50 countries.
Their client base consists of enterprises of all sizes, including
more than 100 Fortune 500 companies. This growing client base
relies on Technavio's comprehensive coverage, extensive research,
and actionable market insights to identify opportunities in
existing and potential markets and assess their competitive
positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com
Report:
www.technavio.com/report/anaplastic-lymphoma-kinase-alk-inhibitors-market-industry-analysis
View original content to download
multimedia:http://www.prnewswire.com/news-releases/-3-43-billion-growth-expected-in-anaplastic-lymphoma-kinase-alk-inhibitors-market--20-14-yoy-growth-in-2021-amid-covid-19-spread--north-america-to-notice-maximum-growth--technavio-301291552.html
SOURCE Technavio